OGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oragenics Inc (OGEN) is not a strong buy for a beginner, long-term investor at this time. The lack of significant positive catalysts, poor financial performance, and absence of trading signals suggest that the stock does not currently present a compelling investment opportunity. Holding off on investment until stronger signals or improvements in fundamentals emerge would be prudent.
The MACD is slightly positive but contracting, RSI is neutral at 40.408, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 0.676, with support at 0.592 and resistance at 0.76.
The company has initiated a Phase IIa clinical trial for ONP-002, which could be a long-term growth driver if successful.
The company's financials are weak, with a significant drop in net income (-31.72% YoY) and EPS (-93.59% YoY). No significant insider or hedge fund activity, and no recent congress trading data.
In Q4 2025, revenue remained at 0 with no growth, net income dropped to -$2,286,870, and EPS declined significantly to -0.54. The company shows no signs of profitability or revenue growth.
No analyst rating or price target data available.
